Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

Witnessing rays of hope as the first Ebola treatment wins approval by FDA

Is the pandemic interfering with the treatment for other diseases?

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth
  • BiotechToday
  • World

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

bioxone October 19, 2020October 19, 2020

Rohit Bhattacharjee, Amity University Kolkata

Acyl CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme A family that takes part in arachidonic acid metabolism and steroidogenesis. ACSL4 is involved in tumour aggressiveness in breast and prostate tumours through various signal transduction pathways regulation. A well-validated ACSL4 inhibitor, however, has not been reported that hinders the entire exploration of the promising target and its therapeutic application on cancer and steroidogenesis inhibition. But in this regard, PRGL493 is identified as a homology model for ACSL4 and docking based virtual screening. Then it was chemically characterized through NMR and mass spectroscopy.

The inhibitory activity was demonstrated through the inhibition of arachidonic acid transformation into arachidonoyl CoA using recombinant enzyme and cellular models. The compound blocked cell proliferation and tumour growth in both breast and prostate cellular and animal models and sensitized the tumour cells to chemotherapeutic and hormonal treatment. Additionally, PRGL493 inhibited de novo steroid synthesis in testis and adrenal cells, in a mouse model and prostate tumour cells. This work proves the concept for potential application of PRGL493 in clinical practice. Moreover, they might prove keys to therapies aiming at control of tumour growth and drug resistance in tumours that express Acyl CoA synthetase 4 (ACSL4) and rely on steroid synthesis.

Also read: Efficient and cost-effective Bacterial mRNA sequencing causing ribosomal RNA depletion

Source- 

Castillo, A.F., Orlando, U.D., Maloberti, P.M. et al. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumour growth, therapeutic resistance and steroidogenesis. Cell. Mol. Life Sci. (2020). https://doi.org/10.1007/s00018-020-03679-5

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged ACSL4 arachidonic acid breast tumour chemotherapeutics de novo synthesis hormonal treatment inhibitor mass spectroscopy NMR PRGL493 prostate steroidogenesis

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Is the pandemic interfering with the treatment for other diseases?

bioxone October 19, 2020

Camelia Bhattacharyya, Amity University Kolkata The pandemic, that is, the COVID-19 pandemic hit the world all of a sudden, changing infection rates or rather increasing it every day without leaving the world to think of the ways to fight with the unknown enemy, the virus. This created a lot of panic at the beginning of […]

other diseases

Related Post

  • BiotechToday
  • World

REVEALING MOLECULAR MECHANISM OF GRAFTING TECHNIQUES-PLANT PARASITES

bioxone October 13, 2020October 13, 2020

Aishila Kar, Amity University Kolkata Plant parasitism is an occurrence by which the parasite plant latches onto and soak up water and nutrients from another host plant, with the help of an organ called the “haustorium.” Once the haustorium forms, specific enzymes then help in setting up a relationship between the tissues of the parasite […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

The role of pre-capture multiplexing in exome sequencing

BioTech Today July 23, 2021July 22, 2021

Saakshi Bangera, DY Patil School of Biotechnology and Bioinformatics Copy number variation is the phenomenon of deviation of an individual from a diploid state of its genome. Normally, humans have two copies of each locus in their genome. Any deviation from this can cause Mendelian disorders. Due to the availability of short-read sequencing technologies, several […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Ribovore: An rRNA sequence validation system for GenBank submissions

BioTech Today August 15, 2021August 15, 2021

Sayak Banerjee, Amity University Kolkata In the year 1977, the Archaebacteria or Archaea, the third domain of life separate from Bacteria and Eukaryota, was proposed by Carl Woese and George Fox. They had analyzed small subunit ribosomal RNA ( SSU rRNA) oligonucleotide fragments from 13 microbes before establishing this proposal. In the late 1980s, the use of SSU rRNA to describe […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy